The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
|
|
- Brenda Jennings
- 6 years ago
- Views:
Transcription
1 Am J Physiol Endocrinol Metab 300: E1038 E1046, First published March 8, 2011; doi: /ajpendo The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes Asger Lund, 1,2,3 Tina Vilsbøll, 1 Jonatan I. Bagger, 1 Jens J. Holst, 3 and Filip K. Knop 1 1 Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Hellerup; 2 Department of Endocrinology O, Herlev Hospital, Herlev; and 3 Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark Submitted 3 December 2010; accepted in final form 1 March 2011 Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 300: E1038 E1046, First published March 8, 2011; doi: /ajpendo Type 2 diabetes mellitus (T2DM) is associated with reduced suppression of glucagon during oral glucose tolerance test (OGTT), whereas isoglycemic intravenous glucose infusion (IIGI) results in normal glucagon suppression in these patients. We examined the role of the intestinal hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2) in this discrepancy. Glucagon responses were measured during a 3-h 50-g OGTT (day A) and an IIGI (day B) in 10 patients with T2DM [age (mean SE), 51 3 yr; body mass index, 33 2 kg/m 2 ; HbA 1c, %]. During four additional IIGIs, GIP (day C), GLP-1 (day D), GLP-2 (day E) and a combination of the three (day F) were infused intravenously. Isoglycemia during all six study days was obtained. As expected, no suppression of glucagon occurred during the initial phase of the OGTT, whereas significantly (P 0.05) lower plasma levels of glucagon during the first 30 min of the IIGI (day B) were observed. The glucagon response during the IIGI GIP GLP-1 GLP-2 infusion (day F) equaled the inappropriate glucagon response to OGTT (P not significant). The separate GIP infusion (day C) elicited significant hypersecretion of glucagon, whereas GLP-1 infusion (day D) resulted in enhancement of glucagon suppression during IIGI. IIGI GLP-2 infusion (day E) resulted in a glucagon response in the midrange between the glucagon responses to OGTT and IIGI. Our results indicate that the intestinal hormones, GIP, GLP-1, and GLP-2, may play a role in the inappropriate glucagon response to orally ingested glucose in T2DM with, especially, GIP, acting to increase glucagon secretion. gut hormones; incretin hormones; hyperglucagonemia TYPE 2 DIABETES MELLITUS (T2DM) is characterized not only by defects in pancreatic -cell function and insulin action but also by dysfunction of the pancreatic -cell (3). In contrast to subjects with normal glucose tolerance [Supplemental Fig. 1 (Supplemental data for this article may be found on the American Journal of Physiology: Endocrinology and Metabolism website.)], patients with T2DM exhibit elevated plasma glucagon levels in the fasting state, and glucagon concentrations fail to decrease appropriately or even, paradoxically, increase in response to oral glucose tolerance test (OGTT) or meal test (20, 21, 36, 41, 43, 44). This hyperglucagonemia contributes, through a stimulatory effect on hepatic glucose production, to the fasting and postprandial hyperglycemia Address for reprint requests and other correspondence: F. K. Knop, Head of Diabetes Research Division, Dept. of Internal Medicine F, Gentofte Hospital, Univ. of Copenhagen, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark ( filipknop@dadlnet.dk). observed in patients with T2DM (1, 9, 44). Postprandial hyperglucagonemia of T2DM has been proposed to arise as a consequence of insufficient secretion of insulin (known to inhibit glucagon secretion) combined with reduced glucose sensitivity of -cells (the secretion of which is normally inhibited by elevated glucose levels). However, we and others (20, 21, 23, 30) have found that patients with T2DM, in contrast to their inappropriate glucagon response to OGTT, are able to suppress glucagon secretion following isoglycemic intravenous glucose infusion (IIGI) mimicking the plasma glucose profile obtained during OGTT, very much like normal glucose-tolerant subjects (Supplemental Fig. 1). This difference in glucagon responses to oral vs. intravenous glucose administration in patients with T2DM is currently unexplained. Theoretically, it could be attributed to the release of glucagonotropic/glucagonostatic peptides secreted from the gastrointestinal tract, as previously proposed (20, 27). The incretin hormone, glucagon-like peptide-1 (GLP-1), secreted from endocrine L cells in the intestinal mucosa in response to feeding, is known to inhibit glucagon secretion (6, 34), whereas the other incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), has been shown to stimulate glucagon secretion (2, 11, 28, 31, 48). Also, glucagon-like peptide-2 (GLP-2), which is cosecreted with GLP-1, has glucagonotropic properties (8, 29). We speculated that, during OGTT in healthy subjects, the glucagonostatic effects of GLP-1 and insulin outweigh the glucagonotropic effects of GIP and GLP-2, resulting in normal glucagon suppression. In contrast, we hypothesized that this glucagonotropic/glucagonostatic equilibrium of the gastrointestinal hormones is disturbed in patients with T2DM, explaining the difference in glucagon responses to OGTT and IIGI. In the present study, we investigated whether a response similar to the inappropriate glucagon response following OGTT in patents with T2DM could be elicited by infusions of the gastrointestinal hormones GIP, GLP-1, and GLP-2 during IIGI (which normally suppresses glucagon secretion in T2DM patients). RESEARCH DESIGN AND METHODS The study was approved by the Scientific-Ethical Committee of the Capital Region of Denmark (registration no. H-A ) and registered with ClinicalTrials.gov (ID: NCT ). The study was performed in accordance with the Helsinki Declaration II, and written informed consent was obtained from all participants before inclusion. Subjects. Ten patients (4 males) with T2DM [age (mean SE), 51 3 yr; body mass index, kg/m 2 ; fasting plasma glucose (FPG), ; HbA 1c, %; duration of diabetes, yr] were studied. The participants were all diagnosed with T2DM according to the World Health Organization criteria at least six E /11 Copyright 2011 the American Physiological Society
2 E1039 Fig. 1. Plasma glucose concentrations during a 50-g oral glucose tolerance test (OGTT) and isoglycemic iv glucose infusion (IIGI) with infusions of saline, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), or a combination of the three hormones in patients with type 2 diabetes. Data are mean values SE. months before study inclusion. Nine patients were treated with metformin alone and one with metformin and sulfonylurea in combination. None of the patients was treated with other drugs likely to affect the responses of glucose, insulin, C-peptide, or any of the intestinal hormones (GIP, GLP-1, or GLP-2). All participants were negative for both islet cell autoantibodies and glutamate decarboxylase-65 autoantibodies and were well treated with regard to plasma lipids and blood pressure. None of the patients had impaired renal function (normal plasma creatinine and no microalbuminuria), proliferative retinopathy or impaired liver function, or suffered from diabetic neuropathy. Methods. All participants were studied on six different occasions (days A, B, C, D, E, and F) preceded by a screening visit. The experiments were separated by at least 24 h and were performed over a 6-wk period. Before each occasion, the patients had not taken their oral antidiabetic therapy for a period of no less than a week. On all occasions, the patients were studied in the morning after an overnight (10 h) fast, including liquids, medication, and use of tobacco. On the first experimental day (day A), a 3-h 50-g OGTT was performed. A cannula was inserted in a cubital vein for collection of arterialized blood samples. The forearm was placed in a heating box (50 C) throughout the experiment. The participants ingested 50 g of water-free glucose dissolved in 300 ml water over the first 3 min of the experiment. Blood samples were drawn 20, 10, and 0 min before and 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, and 180 min after initiation of ingestion of glucose. Blood was distributed in chilled tubes (on ice) containing EDTA, aprotinin (500 kiu/ml blood; Trasylol; Bayer, Leverkusen, Germany), and a specific dipeptidyl peptidase 4 inhibitor (valine-pyrrolide, final concentration: 0.01 mm; a gift from Novo Nordisk, Bagsværd, Denmark) for analysis of GIP, GLP-1, GLP-2, and glucagon. For analysis of insulin and C-peptide, blood was distributed in plain tubes for coagulation (20 min at room temperature). All samples were centrifuged for 20 min at 1,200 g and 4 C. Plasma samples for GIP, GLP-1, GLP-2, and glucagon analyses were stored at 20 C, and serum samples for insulin and C-peptide analyses were stored at 80 C until analysis. For bedside measurement of plasma glucose, blood was distributed in fluoride tubes and centrifuged immediately at 7,400 g for 2 min at room temperature. Days B, C, D, E, and F were performed following day A in randomized order. On each occasion, an IIGI (20% wt/vol), aiming at duplicating the plasma glucose profile attained during day A, was performed as previously described (20). In addition to the adjustable Fig. 2. Plasma concentrations of GIP (top), GLP-1 (middle), and GLP-2 (bottom) during 50-g OGTT and IIGI (left) and during IIGI with concomitant infusions of saline, GIP, GLP-1, GLP-2, or a combination of the three hormones (right) in patients with type 2 diabetes. Data are mean values SE.
3 E1040 intravenous glucose infusion, intravenous infusions of saline (day B), GIP (day C), GLP-1 (day D), GLP-2 (day E), or GIP GLP-1 GLP-2 (day F) were carried out. The infusion rates of the hormones were varied with the intention to reach high physiological concentrations (see below). Cannulas were inserted in cubital veins in both arms, one for collection of arterialized blood samples (50 C) and one for glucose and hormone infusion. A solution containing GIP, GLP-1, GLP-2, GIP GLP-1 GLP-2, or saline mixed with 10 ml of 5% human albumin was prepared each morning before the experiment. The amount of hormone in the infusate was calculated according to individual patient weights so that the infusion speed was fixed and patient blinding intact. At time 0 min, a continuous infusion of either GIP (4.0 pmol kg 1 min 1 ), GLP-1 (0.6 pmol kg 1 min 1 ), GLP-2 (1.0 pmol kg 1 min 1 ), GIP GLP-1 GLP-2 (in the aforementioned concentrations), or saline was initiated. At time 20 min, the infusion rate was halved, and, at time 50 min, the infusion was stopped. Blood was sampled as on day A. Peptides. Synthetic GIP synthesized by Pegasus Pharma (Hannover, Germany) was received as a gift from Dr. M. Nauck, Diabeteszentrum Bad Lauterberg, Germany. The peptide was dissolved in sterilized water containing 2% human serum albumin and subjected to sterile filtration. Appropriate amounts of peptide for each experimental subject were dispensed into capped vials and stored frozen ( 20 C) under sterile conditions until the day of the experiment. The purity and correctness of structure were confirmed by mass sequence and HPLC analysis. Synthetic GLP-1-(7 36) amide (PolyPeptide Laboratories, Linhamn, Sweden) was dissolved in sterilized water containing 2% human serum albumin and subjected to sterile filtration. The GLP-1 peptide solution was demonstrated to be 97% pure and identical to the natural human peptide by HPLC, mass, and sequence analysis. Synthetic human GLP-2, corresponding to human proglucagon-( ), synthesized by PolyPeptide Laboratories (Wolfenbüttel, Germany), was received as a gift from Dr. P. B. Jeppesen, Department of Medical Gastroenterology, Rigshospitalet, Denmark (13). The peptide, provided as the acetate salt, was mixed with 0.9% NaCl, and 0.5% ammonia was added until the peptide dissolved (ph 8 9); then ph was neutralized using 0.1 M acetic acid. The preparation was subjected to sterile filtration, after which peptide content was confirmed by amino acid analysis. Next, the preparation was dispensed into capped vials and heat sterilized for 20 min at 100 C. The preparation was checked for sterility and kept at 20 C until use. The purity and correctness of structure were confirmed by mass sequence and HPLC analysis. Analyses. Plasma glucose concentrations were measured by the glucose oxidase method, using a glucose analyzer (Yellow Springs Instrument model 2300 STAT plus analyzer; YSI, Yellow Springs, OH). Serum insulin and C-peptide concentrations were measured using a two-sided assay, Electro Chemi Luminescens Immuno Assay (D Roche/Hitachi Modular analytics; Roche Diagnostic, Mannheim, Germany). Total GIP, total GLP-1, intact GLP-2, and glucagon were measured by RIAs as previously described (7, 10, 25, 37a). Glucagon was measured with an assay directed against the COOH-terminal of the glucagon molecule (antibody code no ) and, therefore, measures glucagon of mainly pancreatic origin. The assay does not cross-react with GIP, GLP-1, or GLP-2. Statistical analyses and calculations. Baseline, peak, area under curve (AUC), and incretin effect values are expressed as means SE. For analyses of differences of means between days, repeated-measurement ANOVA (rmanova) after Greenhouse-Geisser (G-G) or Huynh-Feldt (H-F) was performed, depending on the sphericity ( ) assumption (G-G was used if was lower than 0.75, and H-F was used if was higher than 0.75; significance level P 0.05) (16). As post hoc analyses, Bonferroni corrections were used. Differences between time courses were compared using two-factor rmanova. AUC values were calculated using the trapezoid rule and are presented as the total area if nothing else is stated. Insulin secretion rate (ISR) values were calculated by deconvolution of measured C-peptide Table 1. GIP, GLP-1, and GLP-2 Day A (OGTT) Day B (IIGI saline) Day C (IIGI GIP) Day D (IIGI GLP-1) Day E (IIGI GLP-2) Day F (IIGI comb) P (rmanova) GIP Mean baseline, pm AUC, pm 3 h 5, B,C,D,E 1, A,C,F 8, A,B,D,E 1, A,C,F 1, A,C,F 6, B,D,E iauc, pm 30 min B,C,D,E,F A,C,F 2, A,B,D,E 5 24 A,C,F A,C,F 2, A,B,D,E GLP-1 Mean baseline, pm AUC, pm 3 h 3, B,C,D,E,F 2, A,D,F 2, A,D,F 7, A,B,C,E 2, A,D,F 6, A,B,C,E iauc, pm 30 min D,F D,F D,F 2, A,B,C,E D,F 2, A,B,C,E GLP-2 Mean baseline, pm D F A F C,E AUC, pm 3 h 1, B,C,D,E,F 1, A,E,F 1, A,E,F 1, A,E,F 5, A,B,C,D 5, A,B,C,D iauc, pm 30 min B,C,D,E,F A,E,F A,E,F A,E,F 1, A,B,C,D 1, A,B,C,D Data are mean values SE. Mean baseline plasma concentrations, area under curve (AUC) values, and incremental area under curve (iauc) values (0-30 min) for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2) during 50-g oral glucose tolerance test (OGTT) (day A) and isoglycemic iv glucose infusion (IIGI) with infusions of saline (day B), GIP (day C), GLP-1 (day D), GLP-2 (day E), or a combination of the three hormones (comb.) (day F) in patients with type 2 diabetes. Significant (P 0.05) differences between individual responses are indicated ( followed by the letter of the day compared with). rmanova, repeated measurements ANOVA.
4 concentrations and application of population-based parameters for C-peptide kinetics (18, 19, 46). ISR is expressed as picomoles insulin secreted per minute per kilogram body weight. The incretin effect was calculated by relating the difference in -cell secretory responses (AUC for insulin, C-peptide, and ISR) between stimulation with OGTT and IIGI to the response after OGTT, which was taken as 100% [incretin effect (%) 100% (AUC OGTT AUC IIGI)/ AUC OGTT]. The incretin effect of each of the hormone infusions was calculated for the hormone infusion days (days C, D, E, and F) in the same manner as mentioned above by relating the difference in -cell secretory responses between stimulation with IIGI homone(s) and IIGI saline to the response after IIGI hormone(s). RESULTS Glucose. Plasma glucose excursions are displayed in Fig. 1. Fasting plasma glucose concentrations were similar on all experimental days [ranging from to mm; P not significant (NS)], and isoglycemia during all six study days was obtained with no significant differences in AUCs between the days (day A, 2, ; day B, 2, ; day C, 2, ; day D, 2, ; day E, 2, ; day F, 2, pm 3h;P NS). The amount of intravenous glucose needed to copy the plasma glucose profile obtained on day A (using 50 g glucose) was similar on all test days (day B, g; day C, g; day D, g; day E, g; day F, g; P NS). GIP. Time courses for plasma concentrations of total GIP are shown in Fig. 2. Baseline values were similar on all study days (Table 1). During days A (OGTT), C (IIGI GIP), and F (IIGI GIP GLP-1 GLP-2), significant GIP responses were observed (with a greater response during day C compared with day A; Table 1), whereas no significant changes (flat lines) E1041 occurred during days B (IIGI saline), D (IIGI GLP-1), and E (IIGI GLP-2) (Table 1). GLP-1. Time courses for plasma concentrations of total GLP-1 are shown in Fig. 2. Baseline values were similar on all study days (Table 1). During days A (OGTT), D (IIGI GLP-1), and F (IIGI GIP GLP-1 GLP-2), significant GLP-1 responses occurred (with greater responses during days D and F compared with day A; Table 1), whereas no significant changes (flat lines) occurred during days B (IIGI saline), C (IIGI GIP), and E (IIGI GLP-2) (Table 1). GLP-2. Time courses for plasma concentrations of intact GLP-2 are shown in Fig. 2. As indicated in Table 1, mean baseline values on the six study days ranged from 9 to 18 pm (P 0.05). During days A (OGTT), E (IIGI GLP-2), and F (IIGI GIP GLP-1 GLP-2), significant GLP-2 responses occurred (with greater responses during days E and F compared with day A; Table 1), whereas no significant changes (flat lines) occurred during days B (IIGI saline), C (IIGI GIP), and D (IIGI GLP-1) (Table 1). Insulin, C-peptide, ISR, and incretin effect. Time courses for serum insulin and C-peptide concentrations and ISR values are shown in Fig. 3. As indicated in Table 2, similar fasting values of insulin and C-peptide were observed on all experimental days (P NS). No significant differences in total serum insulin responses were observed between the experimental days (Table 2). However, significantly greater initial (0 30 min) serum insulin responses occurred during days C (IIGI GIP), D (IIGI GLP-1), and F (IIGI GIP GLP-1 GLP-2) compared with days B (IIGI) and E (IIGI GLP-2) (Table 2). Incretin effect values calculated on the basis of the three integrated -cell secretory responses (insulin, C-peptide, Fig. 3. Serum concentrations of insulin (top), C-peptide (middle), and insulin secretion rate (ISR) values (bottom) during 50-g OGTT and IIGI (left) and during IIGI with concomitant infusions of saline, GIP, GLP-1, GLP-2, or a combination of the three hormones (right) in patients with type 2 diabetes. Data are mean values SE.
5 E1042 Table 2. -Cell responses and incretin effects Day A (OGTT) Day B (IIGI saline) Day C (IIGI GIP) Day D (IIGI GLP-1) Day E (IIGI GLP-2) Day F (IIGI comb) P (rmanova) Insulin Mean baseline, pm AUC, nm 3 h iauc, pm 30 min 1, D,F C,D,F 2, B,E,F 3, A,B,E C,D,F 5, A,B,C,E C-peptide Mean baseline, pm 1, , , , , , AUC, nm 3 h E D,F E iauc, nm 30 min D,F C,D,F B,E,F A,B,E C,D,F A,B,C,E ISR Mean baseline, pm AUC, pm 3 h 1, , , , E 1, D,F 1, E iauc, pm 30 min D,F 16 6 C,D,F B,E,F A,B,E 8 4 C,E,F A,B,C,E Incretin effect Insulin, % C-peptide, % D C,E D,F E ISR, % D E D,F E Data are mean values SE. Mean baseline concentrations, AUC values, iauc values (0 30 min), and incretin effect values for insulin, C-peptide, insulin secretion rate (ISR) during 50-g OGTT (day A) and IIGI with infusions of saline (day B), GIP (day C), GLP-1 (day D), GLP-2 (day E), or a combination of the three hormones (day F) in patients with type 2 diabetes. Significant (P 0.05) differences between individual responses are indicated ( followed by the letter of the day compared with). and ISR) are given in Table 2. Incretin effect values of the GIP infusion during day C (IIGI GIP) and the GLP-2 infusion during day E (IIGI GLP-2) came out negative, whereas incretin effect values of the GLP-1 infusion during day D (IIGI GLP-1) and during the combined hormone infusion on day F (IIGI GIP GLP-1 GLP-2) were similar to the incretin effect during OGTT (day A) (Table 2). Glucagon. Time courses for plasma glucagon concentrations during the six experimental days are presented in Fig. 4 as absolute values and baseline-subtracted values. As indicated in Table 3, the fasting levels of glucagon were similar on the six different days (P NS). As previously observed (20, 21), differences in glucagon responses during OGTT and IIGI were clearly visible (Figs. 4 and 5 and Supplemental Fig. 2) during the initial min of the experiments. Likewise, the impact of the hormone infusions occurred in that time interval (Fig. 2). Following min, the response curves leveled out (Fig. 4), and, thus, as indicated in Table 3, the total AUC for min were similar between the days (P NS). However, when selectively analyzing the first 30 min of the experiments (Table 3), a highly significant difference in glucagon responses was observed (P 0.006). As shown in Fig. 5, no suppression of glucagon was observed in the initial phase of the OGTT (day A) (P NS), whereas significant suppression was observed during the IIGI (day B) (P 0.021). Days E (IIGI GLP-2) and F (IIGI GIP GLP-1 GLP-2) showed, similarly to day A, a lack of suppression of glucagon (P NS). On day C (IIGI GIP), significant hypersecretion of glucagon (P 0.013) was seen, whereas day D (IIGI GLP-1) resulted in enhancement of glucagon suppression (P 0.005). DISCUSSION In the present study, we analyzed the possible role of the gut hormones GIP, GLP-1, and GLP-2 in the inappropriate glucagon response to OGTT observed in patients with T2DM, using IIGI (which in itself results in suppression of glucagon secretion in T2DM) plus separate and combined intravenous infusions of the three hormones. We were able to mimic the inappropriate OGTT-induced glucagon response using IIGI plus combined infusion of GIP, GLP-1, and GLP-2, and we show that glucagon suppression during IIGI is potentiated by intravenous GLP-1 and overruled and reversed to hypersecretion by intravenous GIP. IIGI and concomitant intravenous GLP-2 elicited glucagon responses in the midrange between IIGI and OGTT. The unexpected finding that diminished glucagon suppression is observed in patients with T2DM during OGTT but not following isoglycemic intravenous glucose administration (20, 21, 23, 30) is still unexplained. A lighter version of the phenomenon has been observed in healthy subjects, especially when larger oral glucose loads are applied (23, 27). Both glucose and insulin are known to have potent glucagonostatic effects (15, 17, 37, 40, 47) and have been proposed to be the main responsible factors for the glucagon suppression observed in healthy subjects following administration of glucose. In T2DM, reduced -cell sensitivity to glucose and insulin combined with reduced insulin secretion have been proposed to constitute the most important mechanisms behind the hyperglucagonemic component of the disease (4, 12, 49). However, recent findings of isolated glucagon hypersecretion during
6 E1043 Fig. 4. Plasma glucagon concentrations (top) and baseline-subtracted plasma glucagon values (bottom) during 50-g OGTT and IIGI (left) and during IIGI with concomitant infusions of saline, GIP, GLP-1, GLP-2, or a combination of the three hormones (right) in patients with type 2 diabetes. Data are mean values SE. OGTT and glucagon suppression during IIGI in patients with T2DM (20, 21, 23, 30) question that changes in concentration and/or effect of glucose and/or insulin are responsible for the inappropriate glucagon secretion following oral glucose stimulation in these patients. First, the differential glucagon responses (during oral vs. iv glucose) occur during isoglycemic conditions, ruling out differences in plasma glucose concentrations as the culprit. Second, the inappropriate suppression of glucagon occurs during OGTT when insulin secretion is higher compared with IIGI (20, 21, 23, 30). Thus differences in glucose or -cell secretion during the two glucose stimuli do not seem to explain the OGTT-induced hypersecretion of glucagon. In 2007, we (20) and Meier et al. (27) proposed that glucagonotropic/glucagonostatic gastrointestinal hormones secreted in response to oral glucose might play a role in the different glucagon responses to OGTT and IIGI. This hypothesis was tested in the present study. It is well acknowledged that the concentrations of endogenous GIP, GLP-1, and GLP-2 are severalfold higher in the intestinal and the portal circulation compared with the peripheral circulation (11). Therefore, the infusions of GIP, GLP-1, and GLP-2 were designed to reach high physiological plasma concentrations (measured peripherally) to ensure high enough plasma concentrations in the intestinal and portal circulation so that both endocrine and potential neural pathways (originating from the small intestinal wall or the portal circulation) regulating -cell secretion would be activated. However, our patients exhibited smaller GIP and especially GLP-1 and GLP-2 responses than expected, and our infusions therefore resulted in higher plasma concentrations of GIP, GLP-1, and GLP-2, respectively, compared with the endogenous responses during the 50-g OGTT. Previous studies, however, have reported peak levels of total GIP reaching 142 pm and total GLP-1 reaching 69 pm following 75-g OGTT (23); and postprandial peak levels of intact GLP-2 have been reported to amount to 73 pm (7). Thus, the present peak concentration of total GIP ( 135 pm) can be regarded physiological, whereas the peak levels of GLP-1 ( 135 pm) and GLP-2 ( 100 pm) are slightly supraphysiological, but sometimes seen, e.g., after gastrectomies or gastric bypass operations (26, 42). Nevertheless, we are well aware that the infusions utilized (designed to result in high physiological levels) unfortunately resulted in too high plasma concentrations exceeding the endogenous responses to a higher extent than expected. Thus a study with peripheral plasma concentrations of GIP, GLP-1, and GLP-2 (during the IIGI) equivalent to those observed during the OGTT most likely would yield valuable data (even though they would be criticized for not being comparable to the higher OGTT-induced concentrations in the intestinal and portal circulation). It is well established that GLP-1 possesses a potent glucagonostatic effect, both in healthy subjects and in patients with T2DM (6, 34), and, as expected, the intravenous GLP-1 infusion given concomitantly with the IIGI in the present study resulted in potentiation of glucagon suppression. These findings, combined with the fact that most studies utilizing OGTTs report normal or even increased GLP-1 responses in patients with T2DM compared with matched healthy control subjects (20 22, 33), suggest that type 2 diabetic hypersecretion of Table 3. Glucagon Glucagon Day A (OGTT) Day B (IIGI saline) Day C (IIGI GIP) Day D (IIGI GLP-1) Day E (IIGI GLP-2) Day F (IIGI comb) P (rmanova) Mean baseline, pm AUC, pm 3 h 1, , , , iauc, pm 30 min *, C 45 15*, B,D 45 12*, C Data are mean values SE. Mean baseline concentrations, AUC values, and iauc values (0-30 min) for glucagon during 50-g OGTT (day A) and IIGI with infusions of saline (day B), GIP (day C), GLP-1 (day D), GLP-2 (day E), or a combination of the three hormones (day F) in patients with type 2 diabetes. Significant (P 0.05) differences between individual responses are indicated ( followed by the letter of the day compared with). *Significant differences from 0.
7 E1044 Fig. 5. Initial glucagon responses. Initial glucagon responses expressed as incremental area under curve (iauc) values (means SE) during 50-g OGTT and IIGI and during IIGI with concomitant infusions of saline, GIP, GLP-1, GLP-2, or a combination of the three hormones in patients with type 2 diabetes. *Significant differences (P 0.05) from 0. glucagon following OGTT is not a result of disturbed GLP-1 secretion (8) or effect (6). GLP-2 has been shown to stimulate glucagon secretion in rats and in healthy human subjects at both physiological and supraphysiological doses (8, 29, 45). However, an effect of GLP-2 on glucagon release has to our knowledge not been reported in patients with T2DM; and the insignificant effect of GLP-2 on glucagon responses observed in this study, combined with unpublished data showing normal postprandial GLP-2 responses in patients with T2DM (F. K. Knop, K. J. Hare, J. Pedersen, J. W. Hendel, S. S. Poulsen, J. J. Holst, and T. Vilsbøll, unpublished observation), suggests that OGTT-induced hypersecretion of glucagon in T2DM is not a consequence of exaggerated secretion or effect of GLP-2. GIP has, in addition to its insulinotropic effect [which is severely compromised in T2DM (31)], been shown to possess glucagonotropic properties, both in healthy subjects and in patients with T2DM (2, 28, 31, 48). This bifunctional role of GIP is believed to prevent reactive hypoglycemia and provide a smooth landing for plasma glucose concentrations following postprandial rises. Previous studies have mainly looked at glucagon release in response to supraphysiological levels of GIP (2, 31, 48), or at the effect of GIP in healthy subjects during euglycemic conditions (28). In the present study, we show that plasma GIP concentrations corresponding to physiological postprandial levels of GIP have a clear glucagonotropic effect in patients with T2DM when plasma glucose rises in the same way as during oral ingestion of glucose. This effect coincided with a significant early phase insulin response (excluding falling insulin as a factor), supporting the notion that GIP has a direct effect on pancreatic -cells, as suggested by studies performed in isolated perfused rat pancreata (38). Interestingly, elevated GIP responses have been reported in patients with T2DM (14) and in their healthy offspring (35). Furthermore, glucose homeostatic dysregulation in healthy subjects results in exaggerated OGTT-induced GIP responses (5), and gestational diabetes mellitus is associated with increased postprandial GIP responses, which normalize following delivery and reversion to normal glucose tolerance (L. Bonde, T. Vilsbøll, T. Nielsen, J. Svare, J. J. Holst, S. Larsen, and F. K. Knop, unpublished observations). Thus, potentially, glucagonotropic GIP signaling combined with increased GIP secretion in T2DM may play a hitherto overlooked causal role in the inappropriate glucagon responses of T2DM. The present design cannot rule out that other mechanisms (for instance, neuronal stimulation of glucagon release via nerve fibers in the intestinal mucosa, secretion of glucagon from endocrine cells in the small intestinal mucosa, or reduced renal glucagon extraction) could be involved in the diminished glucagon suppression after oral ingestion of glucose. However, the fact that we, by IIGI and concomitant infusion of the gastrointestinal hormones GIP, GLP-1, and GLP-2 (normally secreted in response to ingestion of nutrients, including glucose), were able to reproduce the inappropriate glucagon response observed in patients with T2DM during OGTT supports that these gastrointestinal hormones play a significant role. The exact mechanisms by which these peptides exert their effects on the -cells are not fully elucidated, and the present study does not allow us to discern between direct or indirect effects of the hormones on pancreatic -cells. A potential limitation of isoglycemic clamp studies is that, by design, the oral glucose challenge has to be carried out before the IIGI, entailing a potential risk of an order effect. In the present study, the five different IIGIs were performed in randomized order following the initial OGTT experiment, eliminating potential order effects of the hormone infusions. Nevertheless, like others (27), we observed that fasting glucagon levels tended to be highest on the first experimental day (OGTT). However, the inappropriate glucagon response was still apparent when glucagon values were expressed as incremental AUC. Therefore, the observed differences in the suppression of glucagon secretion between OGTT and IIGI are unlikely to be due to an order effect. The isoglycemic clamp technique was developed to quantify the incretin effect (32, 39). The incretin effect is defined as the potentiation of insulin secretion exerted by the incretin hormones released after ingestion of nutrients (OGTT). In the present study, the incretin effect amounted to 6%, a severe reduction compared with obese healthy subjects (41%) (24). Interestingly, when we calculated the incretin effect of the individual and the combined infusion, we observed incretin effects equaling the incretin effect during OGTT when GLP-1 was infused (days D and F) [in accordance with the impaired but not eliminated insulinotropic effect of GLP-1 in patients with T2DM (48)] and negative incretin effects when individual GIP or GLP-2 infusions were applied (in accordance with the lost insulinotropic effect of GIP in T2DM and the lack of effect of GLP-2 on insulin secretion). In conclusion, our results indicate that the inappropriate hyperglucagonemic response to orally ingested glucose in type 2 diabetes may be dependent on the release of the intestinal hormones, GIP, GLP-1, and GLP-2, with GIP playing the predominant role in this pathophysiological trait. ACKNOWLEDGMENTS We thank all participants for spending time on this project, and we are grateful for technical assistance from Sofie P. Olesen, Lene Albæk, Ulla K. Hansen, Tonni L. Hansen, and Dorthe Mogensen. GRANTS This study was supported by unrestricted grants from the Danish Diabetes Association, the Novo Nordisk Foundation, and The Danish Council for Independent Research, Medical Sciences.
8 E1045 DISCLOSURES The authors have nothing to disclose. REFERENCES 1. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36: , Chia CW, Carlson OD, Kim W, Shin Y, Charles CP, Kim HS, Melvin DL, Egan JM. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in T ype 2 diabetes. Diabetes 58: , Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28: , Hamaguchi T, Fukushima H, Uehara M, Wada S, Shirotani T, Kishikawa H, Ichinose K, Yamaguchi K, Shichiri M. Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells. Diabetologia 34: , Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab 96: , Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ, Vilsbøll T. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 94: , Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ. In vivo and in vitro degradation of glucagonlike peptide-2 in humans. J Clin Endocrinol Metab 85: , de Heer J, Pedersen J, Orskov C, Holst JJ. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 50: , Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metab Clin Exp 54: , Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33 69) of glicentin. Biochem J 207: , Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87: , Hope KM, Tran POT, Zhou H, Oseid E, Leroy E, Robertson RP. Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the switch-off hypothesis. Diabetes 53: , Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120: , Jones IR, Owens DR, Luzio S, Williams S, Hayes TM. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32: , Kaneko K, Shirotani T, Araki E, Matsumoto K, Taguchi T, Motoshima H, Yoshizato K, Kishikawa H, Shichiri M. Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1 G9 cells. Diabetes Res Clin Pract 44: 83 92, Keselman HJ, Algina J, Kowalchuk RK. The analysis of repeated measures designs: a review. Br J Math Stat Psychol 54: 1 20, Kisanuki K, Kishikawa H, Araki E, Shirotani T, Uehara M, Isami S, Ura S, Jinnouchi H, Miyamura N, Shichiri M. Expression of insulin receptor on clonal pancreatic alpha cells and its possible role for insulinstimulated negative regulation of glucagon secretion. Diabetologia 38: , Kjems LL, Christiansen E, Vølund A, Bergman RN, Madsbad S. Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 49: , Kjems LL, Vølund A, Madsbad S. Quantification of beta-cell function during IVGTT in Type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods. Diabetologia 44: , Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic iv glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 50: , Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T. Reduced Incretin Effect in Type 2 Diabetes. Diabetes 56: , Knop F, Bagger J, Lund A, Vestergaard H, Holst J, Vilsbøll T. Glucagon responses to increasing oral loads of glucose and corresponding isoglycemic intravenous glucose infusions in patients with type 2 diabetes and healthy subjects. Diabetes 58: A368 A368, Knop F, Aaboe K, Vilsbøll T, Madsbad S, Krarup T, Holst J. Reduced incretin effect in obese subjects with normal glucose tolerance as compared to lean control subjects (Abstract). Diabetologia 51: 637, Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 56: , Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30: , Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 50: , Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46: , Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 130: 44 54, Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, Holst JJ, Ferrannini E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57: , Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7 36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: , Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: , Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54: 10 18, Nauck MA, Weber I, Bach I, Richter S, Ørskov C, Holst JJ, Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7 36 amide] or [7 37]) in type 2 diabetic patients. Diabet Med 15: , Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KG, Holst JJ, Schmitz O. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 42: , Ohneda A, Watanabe K, Horigome K, Sakai T, Kai Y, Oikawa S. Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. J Clin Endocrinol Metab 46: , Olsen HL, Theander S, Bokvist K, Buschard K, Wollheim CB, Gromada J. Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology 146: , a.Ørskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide amide and glucagonlike peptide in healthy subjects are indistinguishable. Diabetes 42: , 1993.
9 E Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 103: , Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest 46: , Ravier MA, Rutter GA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 54: , Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64: , le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R, Ghatei MA, Patel A, Bloom SR, Aylwin SJB. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg 252: 50 56, Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol Endocrinol Metab 277: E283 E290, Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85: , Sørensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 27: , Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41: , Vieira E, Salehi A, Gylfe E. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia 50: , Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45: , Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74: , 1984.
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
Diabetologia (2002) 45:1111 1119 DOI 10.1007/s00125-002-0878-6 Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients T. Vilsbøll 1, 2, T. Krarup
More informationElectronic Supplementary Material to the article entitled Altered pattern of the
Electronic Supplementary Material to the article entitled Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic Integrated
More informationIncretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young Type 2 and Type 3
2838 Diabetes Volume 63, August 2014 Signe H. Østoft, 1,2,3 Jonatan I. Bagger, 1,2,3 Torben Hansen, 3,4 Oluf Pedersen, 3 Jens J. Holst, 2,3 Filip K. Knop, 1,2,3 and Tina Vilsbøll 1 Incretin Effect and
More informationThe enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans
The enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans Young Min Cho, MD, PhD Division of Endocrinology and Metabolism Seoul National University College of Medicine Plasma glucose
More informationReduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance
Diabetologia (5) 5:9 9 DOI.7/s5-5-5-y ARTICLE Reduction of insulinotropic properties of GLP- and GIP after glucocorticoid-induced insulin resistance Marie Eriksen & David H. Jensen & Siri Tribler & Jens
More informationThe phenomenon that oral glucose elicits a higher. Original Article Reduced Incretin Effect in Type 2 Diabetes
Original Article Reduced Incretin Effect in Type 2 Diabetes Cause or Consequence of the Diabetic State? Filip K. Knop, 1,2 Tina Vilsbøll, 1 Patricia V. Højberg, 1 Steen Larsen, 3 Sten Madsbad, 4 Aage Vølund,
More informationARTICLE. D. H. Jensen & K. Aaboe & J. E. Henriksen & A. Vølund & J. J. Holst & S. Madsbad & T. Krarup
Diabetologia () :1 11 DOI.7/s--9-7 ARTICLE Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives
More informationNear normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes
Diabetologia (28) 1:632 64 DOI 1.17/s1-8-943-x ARTICLE Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes
More informationIntact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes
Or i g i n a l Advance Publication Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes Soushou Lee*, Daisuke Yabe**, Kyoko Nohtomi*, Michiya Takada*, Ryou
More informationCharacterization of GLP-1 Effects on -Cell Function After Meal Ingestion in Humans
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Characterization of GLP-1 Effects on -Cell Function After Meal Ingestion in Humans BO AHRÉN, MD, PHD 1 JENS J. HOLST, MD, PHD 2 ANDREA
More informationGlucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes
72 Diabetes Volume 64, January 2015 Mikkel Christensen, 1,2 Salvatore Calanna, 1,3 Alexander H. Sparre-Ulrich, 1,4 Peter L. Kristensen, 5 Mette M. Rosenkilde, 4 Jens Faber, 6 Francesco Purrello, 3 Gerrit
More informationBlood glucose concentrations in healthy humans
ORIGINAL ARTICLE Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test Marzieh Salehi, 1 Benedict Aulinger, 1 and David A. D Alessio 1,2 The incretin effect,
More informationAbnormalities in the secretion and insulinotropic
ORIGINAL ARTICLE GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes Nikolaos Mentis, 1 Irfan Vardarli, 1 Lars D. Köthe, 1 Jens J. Holst, 2 Carolyn
More informationEffect of Glucagon-Like Peptide-1 on - and -Cell Function in C-Peptide-Negative Type 1 Diabetic Patients
ORIGINAL ARTICLE Endocrine Research Brief Report Effect of Glucagon-Like Peptide-1 on - and -Cell Function in C-Peptide-Negative Type 1 Diabetic Patients Urd Kielgast, Meena Asmar, Sten Madsbad, and Jens
More informationAn integrated glucose homeostasis model of glucose, insulin, C-peptide, GLP-1, GIP and glucagon in healthy subjects and patients with type 2 diabetes
An integrated glucose homeostasis model of glucose, insulin, C-peptide, GLP-1, GIP and glucagon in healthy subjects and patients with type 2 diabetes Oskar Alskär, Jonatan Bagger, Rikke Røge, Kanji Komatsu,
More informationIncreased postprandial responses of GLP-1 and GIP in patients with. chronic pancreatitis and steatorrhea following pancreatic enzyme
Page 1 of 33 Articles in PresS. Am J Physiol Endocrinol Metab (September 5, 2006). doi:10.1152/ajpendo.00059.2006 Increased insulin after pancreatic enzyme substitution 1 Increased postprandial responses
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationSecretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
Diabetologia (2013) 56:965 972 DOI 10.1007/s00125-013-2841-0 SYSTEMATIC REVIEW Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationGlucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes
Page 1 of 19 Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Mikkel Christensen* 1,2, Salvatore Calanna* 1,3, Alexander H. Sparre-Ulrich 1,4, Peter L.
More informationPREDICTORS OF INCRETIN CONCENTRATIONS IN SUBJECTS WITH NORMAL, IMPAIRED, AND DIABETIC GLUCOSE TOLERANCE
Diabetes Publish Ahead of Print, published online December 5, 27 PREDICTORS OF INCRETIN CONCENTRATIONS IN SUBJECTS WITH NORMAL, IMPAIRED, AND DIABETIC GLUCOSE TOLERANCE Kirsten Vollmer 1, Jens J. Holst
More informationGastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease
http://www.kidney-international.org & 213 International Society of Nephrology Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease Thomas
More information28 Regulation of Fasting and Post-
28 Regulation of Fasting and Post- Prandial Glucose Metabolism Keywords: Type 2 Diabetes, endogenous glucose production, splanchnic glucose uptake, gluconeo-genesis, glycogenolysis, glucose effectiveness.
More informationARTICLE. P. V. Højberg & T. Vilsbøll & R. Rabøl & F. K. Knop & M. Bache & T. Krarup & J. J. Holst & S. Madsbad
Diabetologia (29) 52:199 27 DOI 1.17/s125-8-1195-5 ARTICLE Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic
More informationHyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?
Diabetologia (2014) 57:1919 1926 DOI 10.1007/s00125-014-3283-z ARTICLE Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Nicolai J. Wewer Albrechtsen
More informationNIH Public Access Author Manuscript Diabetologia. Author manuscript; available in PMC 2014 February 01.
NIH Public Access Author Manuscript Published in final edited form as: Diabetologia. 2013 February ; 56(2): 231 233. doi:10.1007/s00125-012-2788-6. Lipotoxicity impairs incretin signalling V. Poitout 1,2
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationGlucagon secretion in relation to insulin sensitivity in healthy subjects
Diabetologia (2006) 49: 117 122 DOI 10.1007/s00125-005-0056-8 ARTICLE B. Ahrén Glucagon secretion in relation to insulin sensitivity in healthy subjects Received: 4 July 2005 / Accepted: 12 September 2005
More informationAppetite, Glycemia and Entero-Insular Hormone Responses Differ Between Oral, Gastric-Remnant and Duodenal Administration of a Mixed Meal Test After
Appetite, Glycemia and Entero-Insular Hormone Responses Differ Between Oral, Gastric-Remnant and Duodenal Administration of a Mixed Meal Test After Roux-en-Y Gastric Bypass June 2018 How a surgical complication
More informationClinical Study. Abstract. Introduction. N A Rhee 1,2, S H Østoft 1, J J Holst 2, C F Deacon 2, T Vilsbøll 1 and F K Knop 1,2
Clinical Study N A Rhee and others Impact of DPP inhibition on 171:3 353 3 The impact of dipeptidyl peptidase inhibition on, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationBiomedical Research 2017; 28 (4): Effects of insulin therapy on glucagon in patients with newly diagnosed type 2 diabetes.
Biomedical Research 2017; 28 (4): 1832-1839 ISSN 0970-938X www.biomedres.info Effects of insulin therapy on glucagon in patients with newly diagnosed type 2 diabetes. Yuanyuan He 1#, Bo Wu 2#, Mei Meng
More informationGlucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia
1076 Diabetes Care Volume 37, April 2014 Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia Caroline K. Kramer, 1,2 Carla A. Borgo~no, 3 Paula Van Nostrand, 1
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationla prise en charge du diabète de
N21 XIII Congrès National de Diabétologie, 29 mai 2011, Alger Intérêt et place des Anti DPP4 dans la prise en charge du diabète de type 2 Nicolas PAQUOT, MD, PhD CHU Sart-Tilman, Université de Liège Belgique
More informationThe glucagon response to oral glucose challenge in Type 1 Diabetes. Mellitus: Lack of Impact of euglycemia
Page 1 of 21 The glucagon response to oral glucose challenge in Type 1 Diabetes Mellitus: Lack of Impact of euglycemia Caroline K Kramer MD PhD 1,2*, Carla A Borgoño MD PhD 3*, Paula Van Nostrand RN 1,
More informationMy Journey in Endocrinology. Samuel Cataland M.D
My Journey in Endocrinology Samuel Cataland M.D. 1968-2015 Drs Berson M.D. Yalow phd Insulin Radioimmunoassay Nobel Prize Physiology or Medicine 1977 Rosalyn Yalow: Radioimmunoassay Technology Andrew Schally
More informationAlternative insulin delivery systems: how demanding should the patient be?
Diabetologia (1997) 4: S97 S11 Springer-Verlag 1997 Alternative insulin delivery systems: how demanding should the patient be? K.S. Polonsky, M. M. Byrne, J. Sturis Department of Medicine, The University
More informationDiabetes Care Publish Ahead of Print, published online November 16, 2009
Diabetes Care Publish Ahead of Print, published online November 16, 2009 Improved Glucose Tolerance After Gastric Bypass Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding
More informationDiscussion & Conclusion
Discussion & Conclusion 7. Discussion DPP-4 inhibitors augment the effects of incretin hormones by prolonging their half-life and represent a new therapeutic approach for the treatment of type 2 diabetes
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationBARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS
BARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS George Vl Valsamakis European Scope Fellow Obesity Visiting iti Associate Prof Warwick Medical School Diabetes is an increasing healthcare epidemic throughout
More informationTreating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric
Treating Type 2 Diabetes with Bariatric Surgery Number (in Millions) of Persons with Diagnosed Diabetes, United States, 198 25 The number of Americans with diabetes increased from 5.6 to 15.8 million Guilherme
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Zibar K., Knežević Ćuća J., Blaslov K., Bulum T., Smirčić-Duvnjak L. (2015) Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes
More informationDiabetes in Chronic Pancreatitis: When is it type 3c? Melena Bellin, MD Associate Professor, Pediatrics & Surgery Schulze Diabetes Institute
Diabetes in Chronic Pancreatitis: When is it type 3c? Melena Bellin, MD Associate Professor, Pediatrics & Surgery Schulze Diabetes Institute Disclosure Information Melena D. Bellin Disclosure of Relevant
More informationEffects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and Isoglycemic Intravenous Glucose
Diabetes Volume 63, February 2014 663 Irfan Vardarli, 1 Elisabeth Arndt, 1 Carolyn F. Deacon, 2 Jens J. Holst, 2 and Michael A. Nauck 1 Effects of Sitagliptin and Metformin Treatment on Incretin Hormone
More informationDiabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia
Original Article doi: 1.1111/joim.12462 Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia A. E. Junker 1,2, L. Gluud
More informationSecretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes
Diabetologia (2005) 48: 1872 1881 DOI 10.1007/s00125-005-1863-7 ARTICLE J. J. Meier. B. Gallwitz. M. Askenas. K. Vollmer. C. F. Deacon. J. J. Holst. W. E. Schmidt. M. A. Nauck Secretion of incretin hormones
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More informationENERGY FROM INGESTED NUTREINTS MAY BE USED IMMEDIATELY OR STORED
QUIZ/TEST REVIEW NOTES SECTION 1 SHORT TERM METABOLISM [METABOLISM] Learning Objectives: Identify primary energy stores of the body Differentiate the metabolic processes of the fed and fasted states Explain
More informationHyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
Diabetologia (2005) 48: 1168 1172 DOI 10.1007/s00125-005-1749-8 ARTICLE E. Mannucci. L. Pala. S. Ciani. G. Bardini. A. Pezzatini. I. Sposato. F. Cremasco. A. Ognibene. C. M. Rotella Hyperglycaemia increases
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationPostprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease
Nephrol Dial Transplant (2014) 29: 119 127 doi: 10.1093/ndt/gft353 Advance Access publication 26 September 2013 Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationMegan Lawless. Journal Club. January 20 th, 2011
Megan Lawless Journal Club January 20 th, 2011 Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 Proceedings of the National Academy of Sciences September 2007 Abstract
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationEXENDIN-4 IS A 39-amino acid reptilian peptide that
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(7):3469 3473 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-032001 Exendin-4 Normalized Postcibal
More informationZurich Open Repository and Archive. The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration
More informationDifference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(2) 220 225! The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563214544709 acb.sagepub.com
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationTHE TWO GLUCAGON-LIKE peptides, GLP-1 and
0021-972X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationLUP. Lund University Publications Institutional Repository of Lund University
LUP Lund University Publications Institutional Repository of Lund University This is an author produced version of a paper published in The Journal of clinical endocrinology and metabolism. This paper
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationData from an epidemiologic analysis of
CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated
More informationEffects of subcutaneous glucagon-like peptide 1 (GLP-1 [7 36 amide]) in patients with NIDDM
Diabetologia (1996) 39: 1546 1553 Springer-Verlag 1996 Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7 36 amide]) in patients with NIDDM M.A. Nauck 1, D. Wollschläger 2, J. Werner 2, J.J. Holst
More informationWomen with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect
Diabetologia (17) :13 1353 DOI 1.17/s15-17-5- ARTICLE Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect Signe Foghsgaard 1,,3 & Louise Vedtofte
More informationFactors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus
Original Article Pathophysiology Diabetes Metab J Published online Feb 20, 2019 https://doi.org/10.4093/dmj.2018.0105 pissn 2233-6079 eissn 2233-6087 DIABETES & METABOLISM JOURNAL Factors Related to Blood
More informationGlucagon-like peptide 1(GLP-1)
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Differential Effects of Acute and Extended Infusions of Glucagon-Like Peptide-1 on First- and Second-Phase Insulin Secretion in Diabetic
More informationDiabetes Care Publish Ahead of Print, published online May 18, 2011
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients
More informationSELECTED ABSTRACTS AND POSTER PRESENTATIONS
SELECTED ABSTRACTS AND POSTER PRESENTATIONS The following summaries are based on abstracts and posters presented at the American Diabetes Association s 65th Annual Scientific Sessions held in San Diego,
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationThe Mediterranean Diet: HOW and WHY It Works So Well for T2DM
The Mediterranean Diet: HOW and WHY It Works So Well for T2DM Susan L. Barlow, RD, CDE. Objectives 1. Discuss the effects of meal size on GLP-1 concentrations. 2. Compare and contrast the specific effects
More informationType 2 diabetes results from the interaction of
ORIGINAL ARTICLE Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients Elza Muscelli, 1 Andrea Mari, 2 Arturo Casolaro, 1 Stefania Camastra,
More informationThe Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes
ORIGINAL ARTICLE The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes Hans Juergen Woerle, Lucianno Carneiro,
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationVildagliptin is a potent and selective
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial
More informationLimited Recovery of b-cell Function After Gastric Bypass Despite Clinical Diabetes Remission
1214 Diabetes Volume 63, April 2014 Roxanne Dutia, 1,2 Katrina Brakoniecki, 1,2 Phoebe Bunker, 1,2 Furcy Paultre, 1,2 Peter Homel, 3 André C. Carpentier, 4 James McGinty, 5,6 and Blandine Laferrère 1,2,6,7
More informationRapid Tachyphylaxis of the Glucagon-Like Peptide 1 Induced Deceleration of Gastric Emptying in Humans
ORIGINAL ARTICLE Rapid Tachyphylaxis of the Glucagon-Like Peptide 1 Induced Deceleration of Gastric Emptying in Humans Michael A. Nauck, 1 Guido Kemmeries, 2 Jens J. Holst, 3 and Juris J. Meier 4 OBJECTIVE
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationInitially more rapid small intestinal glucose delivery increases plasma. insulin, GIP and GLP-1, but does not improve overall glycemia in
Articles in PresS. Am J Physiol Endocrinol Metab (May 10, 2005). doi:10.1152/ajpendo.00099.2005 E-00099-2005.R1 Final accepted version 1 Initially more rapid small intestinal glucose delivery increases
More informationCircadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion
Diabetologia (2009) 52:873 881 DOI 10.1007/s00125-009-1288-9 ARTICLE Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion G. Mingrone &
More informationCordoba 01/02/2008. Slides Professor Pierre LEFEBVRE
Cordoba 01/02/2008 Slides Professor Pierre LEFEBVRE Clinical Research in Type 2 Diabetes : Current Status and Future Approaches Pierre Lefèbvre* University of Liège Belgium Granada, Spain, February 2008
More informationThe effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
Am J Physiol Gastrointest Liver Physiol 3: G1117 G117, 13. First published April 1, 13; doi:1.115/ajpgi.35.13. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects
More informationOral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects 1 4
Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects 1 4 Jerry R Greenfield, I Sadaf Farooqi, Julia M Keogh, Elana
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationGlucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine
Diabetologia (1998) 41: 772±777 Ó Springer-Verlag 1998 Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine H. Larsson,
More informationExenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
666 Diabetes Care Volume 37, March 2014 CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes Gayatri Sarkar, 1 May Alattar,
More informationORIGINAL ARTICLE. Effect of Linagliptin on Incretin-axis and Glycaemic Variability in T1DM
28 ORIGINAL ARTICLE Effect of Linagliptin on Incretin-axis and Glycaemic Variability in T1DM S Mukherjee 1, SK Bhadada 1*, N Sachdeva 1, D Badal 1, S Bhansali 1, P Dutta 1, A Bhansali 1 Abstract Backgrounds
More informationAdd-on saxagliptin improves glycemic status among uncontrolled type 2 diabetes mellitus
International Journal of Research in Medical Sciences Pradhan B et al. Int J Res Med Sci. 2018 May;6(5):1682-1686 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20181758
More informationPATHOPHYSIOLOGY Diabetes Volume 63, November Diabetes 2014;63: DOI: /db
3846 Diabetes Volume 63, November 2014 Sara F. Michaliszyn, 1 Andrea Mari, 2 SoJung Lee, 1 Fida Bacha, 3 Hala Tfayli, 4 Lama Farchoukh, 1 Ele Ferrannini, 5 and Silva Arslanian 1,6 b-cell Function, Incretin
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationOBESITY STUDIES RESEARCH DESIGN AND METHODS
3104 Diabetes Volume 64, September 2015 Kim T. Nguyen, 1 Charles J. Billington, 2 Adrian Vella, 3 Qi Wang, 4 Leaque Ahmed, 5 John P. Bantle, 2 Marc Bessler, 5 John E. Connett, 4 William B. Inabnet, 6 Avis
More informationMechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
Adv Ther (2013) 30(2):81 101. DOI 10.1007/s12325-013-0009-4 REVIEW Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes Michael Horowitz Christopher K. Rayner Karen L.
More informationDefining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade
Diabetes Volume 63, March 2014 1079 Benedikt A. Aulinger, 1 Anne Bedorf, 1 Gabriele Kutscherauer, 1 Jocelyn de Heer, 1 Jens J. Holst, 2 Burkhard Göke, 1 and Jörg Schirra 1 Defining the Role of GLP-1 in
More information